Jesduvroq
(Daprodustat)ApprovedSmall molecule
Jesduvroq is a small molecule that works as a HIF-PHI.[2] It is being used across 2 indications, with its most advanced program in Approved.[1]
Jesduvroq is one of 93 small molecule programs targeting Chronic Kidney Disease. It is currently in Approved.
2
Indications
18
Total Trials
3
Active Trials
92
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
172 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Jesduvroq
GGlaxo Dba Glaxosmithkline
Approved
Uloric
TakedaPreclinical
Sovaldi
GileadPreclinical
Glucotrol
PfizerPreclinical
Vemlidy
GileadPreclinical
Lorelco
SanofiPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Verquvo
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
PROCRIT
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Kidney Disease11 trials
Show 8 more trials
Anemia2 trials
ART1 trial
Kidney Disease1 trial
2 more indications
Regulatory
FDA Approval Timeline[4]
Feb 1, 2023
JESDUVROQ
NDA NDA216951
Feb 1, 2023
JESDUVROQ
NDA NDA216951
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Daprodustat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- HIF-PHI[2]
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- GGlaxo Dba Glaxosmithkline